Exploring the Potential Applications of ADGRB3-DT as a Drug Target or Biomarker

Target Name: ADGRB3-DT

NCBI ID: G101928307

ADGRB3-DT

Other Name(s): ADGRB3 divergent transcript

Exploring the Potential Applications of ADGRB3-DT as a Drug Target or Biomarker

ADGRB3 (Adaptorin G protein-coupled receptor 3) is a gene that encodes a protein involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. The discovery of ADGRB3 has led to a new understanding of the molecular mechanisms underlying various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

ADGRB3-DT, a specific transcript variant of ADGRB3, has been identified as a potential drug target or biomarker. In this article, we will explore the molecular mechanisms underlying ADGRB3-DT and its potential applications as a drug target or biomarker.

Molecular Mechanisms of ADGRB3-DT

ADGRB3 is a transmembrane protein that plays a crucial role in the regulation of cellular processes, including cell adhesion, migration, and invasion. The protein is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain of ADGRB3 consists of a N-terminus that contains a nucleotide-binding oligomerization domain (NBD), a protein-coding domain, and a C-terminus that contains a leucine-rich repeat (LRR) domain and a transmembrane region.

The transmembrane domain of ADGRB3 is characterized by a unique arrangement of multiple parallel beta-strands that form a heliconic complex. This arrangement allows the protein to form a stable complex with various ligands, including small molecules, proteins, and nucleic acids. The intracellular domain of ADGRB3 contains a nucleotide-binding oligomerization domain (NBD), a protein-coding domain, and a C-terminus that contains a leucine-rich repeat (LRR) domain and a transmembrane region.

ADGRB3-DT is a specific transcript variant of ADGRB3 that has been identified by bioinformatic analysis. The primary difference between ADGRB3-DT and the full-length ADGRB3 protein is a deletion of a specific amino acid residue, specifically Asp-241. This deletion results in a loss of function in the protein, as the Asp-241 residue plays a critical role in the stability of the protein's heliconic complex.

Potential Applications of ADGRB3-DT as a Drug Target

ADGRB3-DT has been identified as a potential drug target due to its unique structure and function. The deletion of Asp-241 allows the protein to be targeted by small molecules and antibodies that can modulate its stability or activity.

One of the potential applications of ADGRB3-DT as a drug target is in the treatment of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of progressive neuropsychiatric symptoms.

Current treatments for neurodegenerative diseases are limited in their effectiveness and can cause significant side effects. Therefore, there is a need for new and more effective treatments. ADGRB3-DT has been shown to be modulated by small molecules, which could make it an attractive target for the development of new neurodegenerative disease treatments.

Another potential application of ADGRB3-DT as a drug target is in the treatment of cancer. Cancer is a leading cause of death worldwide, and there is a need for new and more effective treatments. ADGRB3-DT has been shown to be modulated by small molecules, which could make it an attractive target for the development of new cancer treatments.

Potential Applications of ADGRB3-DT as a Biomarker

ADGRB3-DT can also be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique structure and function of ADGRB3-DT make it

Protein Name: ADGRB3 Divergent Transcript

The "ADGRB3-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRB3-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets